The N-terminal proline-rich domain of human p53 has been shown to be important for the induction of apoptosis. However, the corresponding region in mouse and other species is not highly conserved and has been less well studied. In this paper, we have characterized mutants with deletions in this region of mouse p53. Our results demonstrate that deletions in the proline-rich domain have varying effects on function ranging from no effect to severe impairment of cell death activity, depending on precisely which residues are deleted. We also show that the mutants differ in their ability to transactivate different p53 target promoters. Although we have been able to obtain mutants selectively impaired for apoptosis, our data are not generally consistent with this region being a functional domain. The data are more consistent with the interpretation that the region influences function by altering local protein structure which may affect promoter discrimination.
The p53 tumor suppressor protein functions to prevent the accumulation of DNA damage in cells exposed to stress (Prives and Hall, 1999) . p53 carries out its genome protection role by transactivating genes that prevent cell division, such as p21
, GADD45, and IGF-BP3, or induces apoptosis through activation of genes such as Bax, Noxa, and killer/DR5 (Prives and Hall, 1999) . Arrest of cell division provides an opportunity for damaged DNA to be repaired, while apoptosis removes potential tumor precursor cells from the population.
A proline-rich domain has been identified in human p53 protein that is necessary for inducing apoptosis (Walker and Levine, 1996; Zhu et al., 1999; Baptiste et al., 2002) . This domain contains 12 proline residues, including four copies of the sequence PXXP. PXXP motifs have been shown to create a binding site for Srchomology-3 (SH3) domains (Yu et al., 1994) . A mutant deleted for the proline-rich domain in human p53 (D62-91) is disabled for apoptosis (Zhu et al., 1999) , but maintains the ability to induce cell cycle arrest. This mutant is incapable of suppressing tumor cell growth in vitro (Walker and Levine, 1996) suggesting that apoptosis is the critical function of p53 in its tumor suppressor role. Further, the proline-rich domain has been shown to be important in the p53 response to DNA-damaging drugs (Baptiste et al., 2002) .
Compared to other domains of p53, which are almost 100% conserved in some species (Soussi et al., 1990) , the proline-rich domain is relatively unconserved. The homologous region of mouse p53 has a relatively low level of amino-acid identity (43%) and contains only seven proline residues and two PXXP motifs (Figure 1 ), while the corresponding p53 region in chicken and invertebrates shows minimal conservation. Despite this, with the exception of chicken, all these p53 proteins have been shown to cause apoptosis in response to DNA damage (Yonish-Rouach et al., 1991; Haupt et al., 1995; Hansen and Braithwaite, 1996; Brodsky et al., 2000; Jin et al., 2000; Ollmann et al., 2000; Bensaad et al., 2001; Derry et al., 2001; Schumacher et al., 2001) . Some evidence does exist, however, suggesting that the proline domain in mouse p53 is also important for apoptosis induction (Ruaro et al., 1997; Sakamura et al., 1997) , but it has not been extensively studied.
To study the mouse proline-rich region in more detail, we created 11 mutants using inverse PCR ( Figure 1a ) and assayed them for their ability to induce cell death. Typical normalized results for all mutants after transfection of mouse embryo fibroblasts (MEFs) are shown in Figure 1b . Wt p53 reduced the number of viable cells to less than 5% of the control. Mutants D14-43, D53-54, D53-88, and D57-88 (Figure 1b ) all reduced cell viability to between 20 and 45% of the control and mutants D44-60, D52-88, D56-88, and D61-88 were similar to wt p53. Mutants D58-88, and D79-88, however, were very impaired, as 75-85% of transfected cells remained viable. Results for D79-88 at this 24 h time point are consistent with those obtained by Sakamura et al. (1997) in transfected human colon cancer cells (LoVo) using a similar mouse p53 deletion mutant (DPP, deleted for residues 79-89); however by 48 h post-transfection, D79-88 was more potent with o40% live cells remaining (data not shown). This was not the case for D58-88 which was still highly impaired at 48 h. Overall, the data are not consistent with the proline-rich domain being necessary for induction of cell death.
Selected mutants were also tested for their ability to cause death in a mouse cell line (7F2, ATCC# CRL-12557) and in two human cell lines that are genetically deficient in p53 (Figure 1c ; Masuda et al., 1987; Rogan et al., 1995) . In these cells, all mutants caused a similar amount of death to wt p53, with the exception of mutant D58-88, which appeared to be quite defective at inducing cell death in all cell lines. These results for D58-88 are similar to those obtained for the human p53Dpro mutant (deleted for residues 62-91) previously reported (Chen et al., 1996; Baptiste et al., 2002) .
Collectively, the results of these experiments suggest that very little of the proline-rich domain is absolutely required for cell death induction. The different results Figure 1 The proline-rich domain of mouse p53 is largely dispensable for cell death induction. (a) Diagram of the N-terminal amino acids of several p53 species. Sequences were obtained from GenBank and aligned using Clustal-W. The proline-rich domain of human p53 and conserved residues in other species are indicated in bold. Below, residues conserved between human and mouse are indicated by shading and conserved box 1 is indicated. Mouse proline domain mutants were constructed from NC9, which expresses wt mouse p53 (Ginsberg et al., 1991) using inverse PCR essentially as described by Imai et al. (1991) except that forward primers were phosphorylated during manufacture to aid ligation and remaining PCR template was removed by Dpn1 digestion. Deletions were confirmed by sequencing. The position of deletions is shown as black lines. (b) The relative ability of the mutants to cause cell death in MEFs. Test plasmid (2 mg) was transfected (Fugene 6 system, Roche) together with the green fluorescent protein (GFP) construct pEGFP-Cl (0.2 mg, Clontech). At 24 h post-transfection, cells were harvested and stained with propidium iodide (PI). GFP was measured on FL1 and PI on FL2. Live cells (GFP þ , PI À ) were discriminated by FACS. Results were normalized against control cells transfected with the GFP construct plus pUC19. Each set of experiments was repeated two to five times. (c) The relative ability of mutants to cause death in various p53 null cells. This was performed as described except for cells that were harvested 48 h posttransfection Influence of the proline-rich region of mouse p53 SJ Edwards et al may be best explained by the mutants having local structural effects on the p53 protein that affect function to varying degrees. To confirm that D58-88 is impaired for cell death ability and D61-88 and D79-88 are not, a survival assay was carried out. SaOS2 cells were cotransfected with wt p53 or mutant constructs along with a plasmid expressing the neomycin resistance gene (CMVneo). Cells were selected for G418 resistance over 3 weeks, then fixed and stained. Transfection of pUC19 alone results in all the cells being killed by G418, but this is prevented by the inclusion of CMVneo in the transfection mixture (Figure 2a) . Transfection with wt p53 resulted in almost no G418 resistant colonies. By contrast, D58-88 generated many colonies, although fewer than pUC19 with CMVneo, but mutants D61-88 and D79-88 caused few colonies. Thus, this more stringent assay confirms that D58-88 is severely impaired for cell death ability, but mutants D61-88 and D79-88 are not. The result with D79-88 is similar to that reported for DPP in SaOS2 cells (Sakamura et al., 1997) .
To address whether the cell death induced by the mutants is due to apoptosis, we examined Annexin-V expression using FACS analysis after transfection of MEFs. Results show that wt p53 caused about a 20-fold increase in apoptosis, which was substantially inhibited by coexpression of Bcl-2 (Figure 2b ). Mutants D14-43 and D79-88 caused apoptosis, but less well than wt p53, while D61-88 showed enhanced apoptotic ability and D58-88 was severely impaired. Similar results were obtained in SaOS2 cells (data not shown). The result for D79-88 appears inconsistent with its impairment for cell death ability seen in the same cell line (Figure 1b) . However, the initial screening for cell death ability in MEFs was performed at 24 h post-transfection and by 48 h, the time at which the apoptosis assay was carried out, this mutant shows greater death activity, as shown for the other cell lines (Figure 1c ). This suggests that for this mutant the ability to cause cell death is delayed compared to mutant D14-43, which induces a similar level of apoptosis.
To exclude the possibility that the consistent failure of mutant D58-88 to induce cell death is due to a failure to express protein or to localize to the nucleus, IIICF/c cells were transfected with wt p53 and several of the proline-rich domain mutants. Cells were harvested for immunoblotting or fixed and stained for immunocytochemistry. All p53 mutants express protein at a similar level to wt p53, although D58-88 expresses slightly more protein (Figure 2c) . Thus, the failure of D58-88 to cause cell death is not due to a failure of expression. In addition, immunocytochemistry showed that all mutants localize to the nucleus (data not shown). Figure 2 Only mutant D58-88 is consistently impaired for cell death ability. Cells were transfected as described for Figure 1. (a) Survival assay. SaOS2 cells were cotransfected with a wt p53 or mutant construct (2 mg) together with a plasmid expressing neomycin resistance (0.2 mg). Transfectants were selected by growing in the presence of 2 mg/ml G418 antibiotic for 3 weeks. Cells were then fixed and stained with crystal violet. (b) Apoptosis assay. Cells were transfected as above. After 48 h, cells were harvested and incubated with Annexin V-biotin (Roche) and PI. Cells were then incubated with streptavidin-fluorescein (Amersham Pharmacia Biotech) before FACS analysis was carried out. Each experiment was carried out in duplicate and samples pooled prior to analysis. Streptavidin was measured on FL1 and PI on FL2. (c) Western blotting. At 48 h post-transfection of IIICF/c cells, protein lysates were prepared. Samples were standardized by cell number and the protein content equivalent to 8 Â 10 4 cells was loaded on a 10% SDS-PAGE gel. Protein extracts were transferred to PVDF membrane (Pall) before incubation with antibodies. Bands were visualized using the Western Breeze alkaline phosphatase chemiluminescent system (Invitrogen). Prestained protein marker (NEB) was used as a size standard. Antibodies: p53 ¼ Ab1 (mouse monoclonal, Santa Cruz); actin ¼ C-11 (goat polyclonal, Santa Cruz), p21 WAF1/CIP1 ¼ Ab-1 (mouse monoclonal, Oncogene)
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To test whether the proline-rich domain mutants retained transactivation ability, cells were transfected with the mutants along with reporter constructs linked to the promoters of p53 target genes. Firstly, the ability to transactivate the MDM2 promoter was assayed. Results for SaOS2 cells are shown in Figure 3a but this was also performed in IIICF/c and MEFs in which similar results were obtained (data not shown). Results show that D14-43 and D79-88 do not activate MDM2 as well as wt p53. In contrast, D58-88 shows a twofold increase in activity compared to wt p53 and D61-88 shows a sixfold increase.
The effect of the mutants on the p21
promoter was examined next. Results (Figure 3a) show that mutants D14-43 and D79-88 were impaired for p21 WAF1/CIP1 transactivation compared to wt p53. Mutant D58-88 showed a similar level of transactivation to wt p53, while D61-88 showed a twofold greater activity than wt p53. The enhanced ability of D61-88 to transactivate the p21 WAF1/CIP1 promoter was confirmed by immunoblotting in IIICF/c cells (Figure 2c ). Endogenous p21 WAF1/CIP1 was expressed more highly by cells transfected with D61-88 than control cells. The level of p21 WAF1/CIP1 in cells transfected with D14-43 or D79-88 was the same or lower than control cells. D58-88 showed similar results to wt p53. The result for D79-88 is different to that of DPP (Sakamura et al., 1997) , which showed that induction of expression of DPP lead to induction of p21 WAF1/CIP1 protein and p21 WAF1/CIP1 in BRK cells.
The ability to transactivate promoters of p53 responsive genes in the apoptosis pathway was also examined. Results for Noxa (Figure 3a) show that D14-43 and D58-88 transactivate the promoter similarly to wt p53. D79-88 is partially impaired for activity and D61-88 shows a threefold increase in activity compared to wt p53. Results for Bax (Figure 3a) show that D58-88 and D61-88 transactivated similarly to wt p53, while D79-88 and D14-43 had reduced ability to transactivate this promoter, but were substantially higher than the negative control.
We also examined the ability of the mutants to transactivate the p21 WAF1/CIP1 promoter in MEFs and in 7F2 cells. Results (Figure 3b) show that in MEFs, D61-88 activates the p21 WAF1/CIP1 promoter to a level 13-fold higher than that of wt p53, which is much higher than we found in previous experiments. By contrast, mutant D58-88 had similar activity to wt p53 and mutants D14-43 and D79-88 had considerably reduced activity as was found in human cells. Results for 7F2 cells were similar to MEFs except for D61-88, which was only slightly higher than wt p53. This result again suggests that D61-88 has enhanced intrinsic activity compared to wt p53, and comparison of MEFs with 7F2 cells suggests that this might be increased further by cooperation between the mutant and endogenous wt p53, although as the cells are not isogenic, other explanations are possible. As with the cell death data, these results suggest again that the proline-rich domain is largely dispensable for transactivation.
Despite being defective for cell death induction, D58-88 in general transactivated all promoters, including apoptotic promoters, with a similar ability to wt p53, as was found for human p53Dpro (Chen et al., 1996; Baptiste et al., 2002, Figure 3 ). To address this paradox, we first considered the possibility that the ability of the mutants to bind DNA had been altered. However, the results of a DNA binding assay (data not shown) showed that mutants D58-88 and D61-88 were similarly able to bind DNA and so these data did not allow us to discriminate between the mutants. This is possibly due to the qualitative nature of gel retardation assays. To circumvent this problem, we hypothesized that D58-88 may have a reduced ability to transactivate death promoters compared to cell cycle promoters. To test this, we titrated the amount of target promoter relative to a fixed amount of mutant or wt p53 construct and carried out reporter assays. If the mutant is less able to transactivate a death promoter relative to a cell cycle promoter, it will only be able to activate the promoter at higher DNA concentrations. Results comparing the ability of wt p53 and D58-88 to activate the Bax and p21 WAF1/CIP1 promoters are shown in Figure 4 , expressed relative to the activity measured with the highest quantity of promoter transfected (1 mg). As the Bax and p21 WAF1/CIP1 promoters are diluted, the ability of wt p53 to transactivate is reduced in almost similar fashion for each promoter. However, while D58-88 shows a similar profile to wt p53 for the p21 WAF1/CIP1 promoter, its ability to activate the Bax promoter declines at much higher target concentrations. This result is consistent with D58-88 having a reduced ability to activate the Bax promoter compared to the p21
promoter, suggesting that the protein has been altered structurally in such a way as to allow discrimination between different promoters. Mutants D14-43 and D79-88 may have been affected similarly, since they were quite defective in transactivating the MDM2 and p21
WAF1/CIP1
promoters but retained ability to activate the Noxa and Bax promoters (Figure 3 ), albeit to varying degrees.
Mutant D61-88 has a wt phenotype in every experiment we have carried out. Indeed, it appears to be better Figure 3 Mutant D58-88 retains wild-type transactivation ability, while D61-88 has augmented ability in human cells. (a) SaOS2 cells were transfected with mutant or wt p53 constructs (1 mg) together with luciferase reporter constructs containing promoter sequences for the indicated p53 target genes (1 mg). p21Dp53 is the p21 WAFI/CIP1 promoter construct lacking the p53 response element. At 48 h post-transfection, luciferase activity was assayed using the Promega Luciferase Assay System. An internal standard was not used as p53 has been shown to repress promoters such as SV40 (Ginsberg et al., 1991; Jackson et al., 1993; Perrem et al., 1995) , which are commonly used to drive control reporters. Instead results were standardized to cell number. Each experiment was carried out in duplicate and repeated two to three times. Error bars indicate s.e.m., except when less than 5%. (b) Transactivation ability of proline domain mutants is similar in mouse cells. MEFs and 7F2 (ATCC CRL-12557) cells were transfected with mutant or wt p53 constructs together with the p21 WAFI/CIP1 luciferase reporter construct or p21Dp53 control and assayed as described above than wt p53 in most experiments, which is not due to enhanced protein expression or to enhanced DNA binding (data not shown). It is therefore intrinsically more active than wt p53. That this mutant is still largely deleted for the proline-rich domain and has only three amino acids more that D58-88 is again consistent with the interpretation that different mutations affect local protein structure differently and therefore that the proline-rich domain itself is not necessary for function.
Mutant D79-88 shows variable ability to cause cell death, apparently dependent on the time of assay. Results from the cell death assay show that at 24 h posttransfection the ability to cause cell death in MEFs is impaired (Figure 1b ), but by 48 h it is more potent (data not shown). This is supported by the data for other cell lines at 48 h (Figure 1c) , by the apoptosis assay (Figure 2b ) and by the survival assay, which is incubated for 3 weeks. These data suggest that D79-88 is moderately impaired for cell death ability but that given sufficient time it can achieve a near wt level of death activity.
Although we have created a mutant deleted for a large proportion of the proline-rich domain of mouse p53 (D58-88) that is selectively defective for causing cell death, similar to human p53 (Chen et al., 1996; Walker and Levine, 1996) other mutants are not, and one mutant, D61-88, has a wild-type phenotype in all assays. These findings are not consistent with the interpretation that the proline-rich region of mouse p53 is an 'apoptotic domain'. Our findings indicate that while it may be important in regulating p53 function, possibly by promoter discrimination, the region does not appear to be a functional domain in the usual sense. Rather, it is more likely that critical amino-acid residues probably influence function, but the region as a whole is largely dispensable. Such an interpretation is consistent with the relatively low sequence conservation in this area compared to other parts of the p53 protein. Influence of the proline-rich region of mouse p53 SJ Edwards et al
